The goal of this observational study is to observe the formation and development of the non-perfusion area of diabetic retinopathy in the posterior area of the retina in type 2 diabetes patients aged 18-75 years old, who can cooperate with all examinations and sign informed consent, clinical myopathy examination and Optos 7 field of vision with mild than severe NPDR, and no other exclusion indicators.The main questions it aims to answer are whether posterior retinal non-perfusion area occurs earlier than peripheral non-perfusion area and whether the rate of non-perfusion area expansion is a risk factor for the progression of diabetic retinopathy. Participants will have protocol-specific follow-up examinations at 1, 2, 3, 4, and 5 years (± 3 months). Additional visits are made as required by the study and the patient's condition. The contents of follow-up examinations are: History of other diseases, medications being used, eye diseases, surgeries, treatments, height, weight, and blood pressure. Best corrected vision, logarithmic visual acuity chart. Tupai OCTA, 24×20mm range, 6×6mm range scan. Optos fundus imaging, color and no red light images. Fundus fluorescence angiography (only preliminary examination for the first time found mild to moderate NPDR patients, who have been angiographed in the past, only at the 5th year, or as required by the condition). Glycosylated hemoglobin. Creatinine, urea, glomerular filtration rate. Total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol. Urinary microalbumin/urinary creatinine ACR. Microvisual field.
Study Type
OBSERVATIONAL
Enrollment
200
Sichuan Academy of Medical Science Sichuan Provincial Hosptial
Chengdu, Sichuan, China
RECRUITINGObservation and follow-up of biomarkers of diabetic retinopathy
The biomarkers of diabetic retinopathy were observed by eye examinations including best corrected visual acuity, logarithmic visual acuity chart, TupaOCTA 24×20mm, 6×6mm scan, Optos fundus color and non-red light images, microvisual field at each follow-up.
Time frame: 2024-2029
Level of Glycosylated hemoglobin
tested by venous blood
Time frame: 2024-2029
Creatinine
tested by venous blood
Time frame: 2024-2029
Total cholesterol
tested by venous blood
Time frame: 2024-2029
Urinary microalbumin
tested by urine
Time frame: 2024-2029
Urea
tested by venous blood
Time frame: 2024-2029
Glomerular filtration rate
tested by venous blood
Time frame: 2024-2029
Triglycerides
tested by venous blood
Time frame: 2024-2029
Low-density lipoprotein cholesterol
tested by venous blood
Time frame: 2024-2029
High-density lipoprotein cholesterol
tested by venous blood
Time frame: 2024-2029
Urinary creatinine ACR
tested by urine
Time frame: 2024-2029
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.